HomeNewsBusinessCOVID-19 a turning point for facilities management services, says India’s second largest provider

COVID-19 a turning point for facilities management services, says India’s second largest provider

Rituraj Sinha, Group Managing Director of SIS, shares how clients have increased focus on keeping their offices and factories disinfected

June 26, 2020 / 13:25 IST
Story continues below Advertisement

Rituraj Sinha's bet in 2009 to diversify SIS, which till then was known for its security business, into facilities management is now helping the company as demand for its services has shot up amid the COVID-19 pandemic.

Companies have increased their focus and spend on sanitation and hygiene as they try to limit the damage to their employees and facilities.

Story continues below Advertisement

These firms are now spending up to 25 percent more on keeping their facilities disinfected.

"The global pandemic has surely changed the way companies think about managing their offices and factories. It is a turning point. While it was a priority earlier too, now safety has become the top most," said Sinha, Group Managing Director, SIS.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show